Bal Pharma Ltd
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services[1]
- Market Cap ₹ 161 Cr.
- Current Price ₹ 101
- High / Low ₹ 158 / 76.3
- Stock P/E 22.2
- Book Value ₹ 48.6
- Dividend Yield 1.19 %
- ROCE 10.1 %
- ROE 9.84 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 37.7%
Cons
- Company has low interest coverage ratio.
- Tax rate seems low
- Company has a low return on equity of 8.51% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
179 | 187 | 198 | 229 | 211 | 225 | 171 | 251 | 281 | 304 | 339 | 303 | |
161 | 170 | 183 | 214 | 194 | 207 | 166 | 226 | 257 | 279 | 307 | 274 | |
Operating Profit | 18 | 17 | 15 | 15 | 17 | 18 | 5 | 25 | 24 | 25 | 32 | 30 |
OPM % | 10% | 9% | 7% | 6% | 8% | 8% | 3% | 10% | 9% | 8% | 9% | 10% |
1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 1 | 3 | 2 | |
Interest | 7 | 7 | 6 | 8 | 9 | 13 | 13 | 12 | 11 | 12 | 15 | 17 |
Depreciation | 5 | 7 | 7 | 6 | 7 | 6 | 8 | 10 | 9 | 9 | 10 | 10 |
Profit before tax | 7 | 5 | 3 | 3 | 3 | -0 | -14 | 4 | 9 | 5 | 9 | 5 |
Tax % | 23% | 25% | 90% | 114% | 87% | -1,175% | -5% | -15% | 38% | 45% | 18% | -41% |
5 | 4 | 1 | -0 | 0 | 2 | -13 | 5 | 6 | 3 | 7 | 7 | |
EPS in Rs | 4.56 | 2.82 | 1.10 | 1.24 | 1.96 | 2.67 | -8.62 | 3.20 | 3.78 | 1.64 | 4.68 | 4.53 |
Dividend Payout % | 22% | 35% | 91% | 81% | 51% | 37% | 0% | 31% | 26% | 61% | 26% | 26% |
Compounded Sales Growth | |
---|---|
10 Years: | 5% |
5 Years: | 12% |
3 Years: | 3% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 21% |
3 Years: | 13% |
TTM: | -2% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 20% |
3 Years: | 1% |
1 Year: | -16% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 13 | 13 | 14 | 14 | 14 | 14 | 15 | 15 | 16 | 16 | 16 |
Reserves | 39 | 42 | 42 | 48 | 51 | 52 | 38 | 39 | 44 | 48 | 53 | 62 |
51 | 49 | 89 | 93 | 110 | 124 | 118 | 110 | 104 | 131 | 140 | 150 | |
54 | 59 | 67 | 78 | 86 | 71 | 68 | 76 | 98 | 116 | 108 | 108 | |
Total Liabilities | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 317 | 336 |
55 | 52 | 56 | 60 | 71 | 70 | 71 | 69 | 67 | 76 | 77 | 87 | |
CWIP | 0 | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 0 | 0 | 3 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 2 |
99 | 111 | 151 | 172 | 188 | 187 | 164 | 172 | 192 | 235 | 233 | 244 | |
Total Assets | 155 | 164 | 211 | 233 | 260 | 261 | 238 | 240 | 261 | 311 | 317 | 336 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
13 | 15 | -19 | 6 | 1 | 8 | 23 | 22 | 27 | -2 | 23 | 20 | |
-7 | -5 | -14 | -8 | -4 | -8 | -5 | -6 | -9 | -22 | -19 | -15 | |
-8 | -7 | 32 | -6 | 4 | 0 | -20 | -17 | -17 | 24 | -1 | -8 | |
Net Cash Flow | -2 | 2 | -1 | -8 | 1 | -0 | -2 | 0 | 0 | 0 | 3 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 93 | 88 | 105 | 99 | 111 | 105 | 106 | 98 | 98 | 113 | 107 | 111 |
Inventory Days | 122 | 132 | 145 | 172 | 240 | 217 | 292 | 146 | 162 | 207 | 167 | 238 |
Days Payable | 129 | 142 | 163 | 171 | 182 | 147 | 167 | 114 | 143 | 167 | 147 | 189 |
Cash Conversion Cycle | 86 | 78 | 87 | 100 | 168 | 175 | 231 | 130 | 117 | 153 | 127 | 161 |
Working Capital Days | 98 | 92 | 142 | 140 | 163 | 166 | 180 | 129 | 109 | 134 | 123 | 152 |
ROCE % | 11% | 7% | 8% | 8% | 7% | -0% | 10% | 12% | 10% | 12% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jun - Results for the quarter and financial year ended 31.03.2025.
-
Board Meeting Outcome for Outcome Of The Board Meeting-Audited Financial Results And Recommendation Of Dividend
29 May - Audited FY25 results approved; 12% dividend recommended; auditors appointed; subsidiary merger completed.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report filed; minor one-day delay fined Rs. 5000; overall compliance confirmed.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
16 May - Whole time director Kotian Chittanand Damodar resigns effective 16 May 2025, no other material reasons.
-
Board Meeting Intimation for Approval Of Audited Financial Results Of The Company And Recommendation Of Dividend, Is Any, For The Financial Year Ended 31.03.2025.
15 May - Board meeting on 29 May 2025 to approve FY25 results, dividend, and appoint auditors.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Business Overview:[1]
BALPL is a fully integrated pharmaceuticals company specialising in Bulk Drugs, Prescription Drugs, Generics, Pharma intermediates, and Ayurvedic products. Company focuses on therapeutic areas viz. Anti-diabetes, Anti-histamine, Anti-inflammatory, Acne Treatment, Gastroenterology, Cardiology, and dermatology. Company is one of Gliclazide's largest producers and exporters, a medicine to treat type-2 diabetes.